Hikma (LON: HIK) launches generic version of Glaxo asthma treatment

2 min read | December 19, 2020 11:26 AM AEDT | By Team Kalkine Media

Google News:

Recent News

Can ASX 200 Energy Transition Leaders Power Ahead?

Can Grid Firming Decide the Next Energy Winners?

Beyond the Banks: Which ASX Miners and Energy Names Are Quietly Paying...

Franking Credits and Income Strategies Across ASX 200 Dividend Portfol...

Make Kalkine Media
My Trusted Source

Hikma Pharmaceutical PLC (LON: HIK) announced on 17 December) that it had received necessary approval required from the Food & Drugs Administration (FDA) for launching its generic version of GlaxoSmithKline's Advair Diskus®.

The dosage strengths to be launched in the US are 100mcg/50mcg and 250mcg/50mcg doses.
Hikma has been Vectura’s partner in developing the proprietary dry powder inhaler and formulation technology. Based in the UK, Vectura Group is a provider of innovative inhaler drug delivery solutions.
The British pharma major’s fluticasone propionate and salmeterol inhalation powder is indicated for the treatment of asthma, the maintenance treatment of airflow obstruction, and for reducing exacerbations in patients with chronic obstructive pulmonary disease (COPD).
The powder is delivered using Vectura’s proprietary lever-operated multi-dose inhaler device technology.
Vectura will receive a payment of $11 million and will also earn a mid-teen royalty on net sales of the product.
An estimated sale of $2 billion in the 12 months ending September 2020 has been recorded for the Fluticasone Propionate and Salmeterol Inhalation Powder USP in the US for 100mcg/50mcg and 250mcg/50mcg, according to IQVIA.
Hikma’s Chief Executive Officer, Siggi Olafsson said that the approval of the generic version of Advair Diskus® has proven to be an important milestone in the company’s strategy in developing more complex respiratory products.
The shares of Hikma Pharmaceuticals surged after the company disclosed that it had received the approval from FDA.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.